Nevertheless, in concert with therapies designed to eradicate C. difficile, agents that selectively target intestinal P2Y6 signaling may prove useful in the treatment of CDI, especially in severe cases that exhibit an exaggerated immune response. This evidence concerns the gene P2RY6 and clostridium difficile infection.